Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.03 | -0.05 | -0.02 |
| FCF Yield | -53.95% | -27.52% | -12.40% | -12.40% |
| EV / EBITDA | -1.95 | -2.22 | -2.14 | -3.46 |
| Quality | ||||
| ROIC | -122.03% | -96.63% | -39.02% | -44.69% |
| Gross Margin | 58.25% | -50.05% | -26.99% | -37.23% |
| Cash Conversion Ratio | 1.01 | 0.61 | – | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 690.55% | 439.09% | 336.90% | 245.23% |
| Free Cash Flow Growth | -45.33% | -56.95% | 8.70% | -72.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | 0.69 | 1.23 | 0.88 |
| Interest Coverage | -89.50 | -401.72 | -335.90 | -339.68 |
| Efficiency | ||||
| Inventory Turnover | 9.71 | 14.97 | 17.66 | 14.09 |
| Cash Conversion Cycle | -16.34 | 2.33 | -4.20 | 30.84 |